Novocure [NVCR] vs Enovis [ENOV] Detailed Stock Comparison
Novocure
NASDAQ
Loading...
Enovis
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Novocure wins in 8 metrics, Enovis wins in 10 metrics, with 0 ties. Enovis appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Novocure | Enovis | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -9.40 | -2.14 | Novocure |
| Price-to-Book Ratio | 4.69 | 0.71 | Enovis |
| Debt-to-Equity Ratio | 200.39 | 56.75 | Enovis |
| PEG Ratio | -0.58 | -0.02 | Novocure |
| EV/EBITDA | -8.99 | 8.97 | Novocure |
| Profit Margin (TTM) | -27.13% | -37.80% | Novocure |
| Operating Margin (TTM) | -24.89% | 2.41% | Enovis |
| EBITDA Margin (TTM) | N/A | 2.41% | N/A |
| Return on Equity | -48.07% | -28.25% | Enovis |
| Return on Assets (TTM) | -8.64% | 0.89% | Enovis |
| Free Cash Flow (TTM) | $-69.22M | $-67.21M | Enovis |
| 1-Year Return | -0.41% | -21.31% | Novocure |
| Price-to-Sales Ratio (TTM) | 2.60 | 0.84 | Enovis |
| Enterprise Value | $1.43B | $3.25B | Enovis |
| EV/Revenue Ratio | 2.27 | 1.49 | Enovis |
| Gross Profit Margin (TTM) | 73.88% | 59.29% | Novocure |
| Revenue per Share (TTM) | $6 | $39 | Enovis |
| Earnings per Share (Diluted) | $-1.56 | $-14.95 | Novocure |
| Beta (Stock Volatility) | 0.75 | 1.80 | Novocure |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Novocure vs Enovis Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Novocure | 4.34% | 13.73% | 21.36% | -17.22% | -13.66% | -51.12% |
| Enovis | 4.81% | 6.77% | 4.44% | -4.84% | -5.24% | -27.72% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Novocure | -0.41% | -81.98% | -89.43% | -30.26% | -19.80% | -19.80% |
| Enovis | -21.31% | -30.29% | -42.20% | -39.91% | 19.48% | -9.24% |
News Based Sentiment: Novocure vs Enovis
Novocure
News based Sentiment: MIXED
Novocure showcased strong clinical trial results and continued revenue growth, but remains unprofitable and faces mixed analyst opinions. The upcoming FDA submissions and Q3 earnings report will be critical catalysts for the stock's performance, creating a mixed investment narrative.
Enovis
News based Sentiment: POSITIVE
October was a notably positive month for Enovis, marked by significant analyst upgrades, substantial insider buying activity, and a clear strategic direction under its new CEO. These developments suggest growing confidence in the company's future prospects and potential for growth, making it a significant month for investors.
Performance & Financial Health Analysis: Novocure vs Enovis
| Metric | NVCR | ENOV |
|---|---|---|
| Market Information | ||
| Market Cap | $1.64B | $1.83B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 2,239,560 | 615,380 |
| 90 Day Avg. Volume | 1,734,680 | 899,257 |
| Last Close | $14.66 | $32.02 |
| 52 Week Range | $10.87 - $34.13 | $25.47 - $49.83 |
| % from 52W High | -57.05% | -35.74% |
| All-Time High | $232.76 (Jun 21, 2021) | $129.72 (Jun 09, 2014) |
| % from All-Time High | -93.70% | -75.32% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.06% | 0.08% |
| Quarterly Earnings Growth | 0.06% | 0.08% |
| Financial Health | ||
| Profit Margin (TTM) | -0.27% | -0.38% |
| Operating Margin (TTM) | -0.25% | 0.02% |
| Return on Equity (TTM) | -0.48% | -0.28% |
| Debt to Equity (MRQ) | 200.39 | 56.75 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $3.13 | $45.11 |
| Cash per Share (MRQ) | $8.15 | $0.77 |
| Operating Cash Flow (TTM) | $-44,676,000 | $188.06M |
| Levered Free Cash Flow (TTM) | $5.94M | $65.68M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | $0.00 |
Valuation & Enterprise Metrics Analysis: Novocure vs Enovis
| Metric | NVCR | ENOV |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -9.40 | -2.14 |
| Forward P/E | -9.77 | 10.13 |
| PEG Ratio | -0.58 | -0.02 |
| Price to Sales (TTM) | 2.60 | 0.84 |
| Price to Book (MRQ) | 4.69 | 0.71 |
| Market Capitalization | ||
| Market Capitalization | $1.64B | $1.83B |
| Enterprise Value | $1.43B | $3.25B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 2.27 | 1.49 |
| Enterprise to EBITDA | -8.99 | 8.97 |
| Risk & Other Metrics | ||
| Beta | 0.75 | 1.80 |
| Book Value per Share (MRQ) | $3.13 | $45.11 |
Financial Statements Comparison: Novocure vs Enovis
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | NVCR | ENOV |
|---|---|---|
| Revenue/Sales | $154.99M | $564.55M |
| Cost of Goods Sold | $38.52M | $229.85M |
| Gross Profit | $116.47M | $334.70M |
| Research & Development | $53.78M | $30.70M |
| Operating Income (EBIT) | $-37.87M | $-16.08M |
| EBITDA | $-34.54M | $55.91M |
| Pre-Tax Income | $-30.30M | $-25.65M |
| Income Tax | $4.02M | $10.80M |
| Net Income (Profit) | $-34.32M | $-36.55M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | NVCR | ENOV |
|---|---|---|
| Cash & Equivalents | $127.28M | $38.46M |
| Total Current Assets | $1.09B | $1.22B |
| Total Current Liabilities | $743.31M | $477.42M |
| Long-Term Debt | $137.76M | $1.42B |
| Total Shareholders Equity | $361.96M | $2.62B |
| Retained Earnings | $-1.19B | $-338.99M |
| Property, Plant & Equipment | $145.02M | $492.24M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | NVCR | ENOV |
|---|---|---|
| Operating Cash Flow | $-14.80M | $-1.07M |
| Capital Expenditures | $-10.61M | $-43.26M |
| Free Cash Flow | $-46.28M | $-44.86M |
| Debt Repayment | $0 | $-15.44M |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | NVCR | ENOV |
|---|---|---|
| Shares Short | 5.89M | 6.93M |
| Short Ratio | 4.33 | 7.31 |
| Short % of Float | 0.08% | 0.18% |
| Average Daily Volume (10 Day) | 2,239,560 | 615,380 |
| Average Daily Volume (90 Day) | 1,734,680 | 899,257 |
| Shares Outstanding | 108.52M | 55.88M |
| Float Shares | 94.06M | 56.42M |
| % Held by Insiders | 0.10% | 0.02% |
| % Held by Institutions | 0.86% | 1.21% |
Dividend Analysis & Yield Comparison: Novocure vs Enovis
| Metric | NVCR | ENOV |
|---|---|---|
| Last 12-Month Dividend | N/A | $0.00 |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | $0.00 |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | $0.00 |
| Ex-Dividend Date | N/A | N/A |